c-FMS (CSF1R, CSF-1R) is a receptor protein-tyrosine kinase of the platelet-derived growth factor receptor (PDGFR) family. The cell surface receptor for IL-34 and CSF1 is called c-FMS. Important functions of c-FMS include regulating haematopoiesis, cell survival, maturation of microglia and monocytes, and immune response regulation.

Osteoclasts and myelomonocytic-lineage cells, like monocytes and macrophages, express c-FMS specifically, and the activation of c-FMS signaling encourages the proliferation or differentiation of these cells. Additionally, it encourages the production of inflammatory mediators like interleukin 6 (IL6) and tumor necrosis factor-alpha (TNF-).

c-Fms related products

Structure Cat No. Product Name CAS No. Product Description
Anumigilimab (CSL-324) V69281 Anumigilimab (CSL-324) 2416593-08-1 Anumigilimab (CSL-324) is a humanized IgG2a monoclonal antibody (mAb) targeting the human granulocyte colony-stimulating factor (G-CSF) receptor.
Axatilimab (SNDX-6352) V69279 Axatilimab (SNDX-6352) 2155851-88-8 Axatilimab (SNDX-6352) is a human IgG4 antibody with high affinity for CSF-1R.
AZD7507 V4238 AZD7507 1041852-85-0 AZD7507 is a novel, potent, selective and orally bioactive 3-amido-4-anilinoquinoline CSF-1R inhibitor with 32 nM cell activity and with antitumor activity.
BPR1R024 mesylate V69288 BPR1R024 mesylate 2763365-40-6 BPR1R024 mesylate is a selective, orally bioactive, colony-stimulating factor-1 receptor (CSF1R) inhibitor.
c-Fms-IN-13 V69274 c-Fms-IN-13 885704-58-5 c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (antagonist) with IC50 of 17 nM.
c-Fms-IN-14 V69272 c-Fms-IN-14 1898210-99-5 c-Fms-IN-14 (Example 76) is a c-Fms inhibitor (antagonist) with IC50 of 4 nM.
Cabiralizumab (FPA 008; Anti-Human CSF1R Recombinant Antibody) V69275 Cabiralizumab (FPA 008; Anti-Human CSF1R Recombinant Antibody) 1613144-80-1 Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (mAb).
cFMS Receptor Inhibitor II V4438 cFMS Receptor Inhibitor II 959860-85-6 cFMS Receptor Inhibitor II (BUN60856; BUN-60856) is a novel, cell-permeable and potent CSF1R (Colony stimulating factor 1 receptor) kinase inhibitor with an IC50 of 80 nM.
cFMS Receptor Inhibitor IV V69284 cFMS Receptor Inhibitor IV 959626-45-0 cFMS receptor blocker/inhibitor IV (Compound 42) is a potent inhibitor of cFMS with IC50 of 0.017 μM.
CSF1R-IN-1 V31740 CSF1R-IN-1 2095849-04-8 CSF1R-IN-1 is an inhibitor (blocker/antagonist) of CSF1R with IC50 of 0.5 nM.
CSF1R-IN-15 V69287 CSF1R-IN-15 2925744-43-8 CSF1R-IN-15 (compound 23) is an inhibitor (blocker/antagonist) of c-Fms.
CSF1R-IN-17 V79871 CSF1R-IN-17 CSF1R-IN-17 (compound 9) is a potent and specific CSF1R antagonist (inhibitor) with IC50 of 0.2 nM.
CSF1R-IN-18 V85452 CSF1R-IN-18
CSF1R-IN-19 V85255 CSF1R-IN-19 1819989-27-9
Edicotinib V3765 Edicotinib 1142363-52-7 Edicotinib (formerly known as JNJ-527; JNJ-40346527) is a novel selective and orally bioavailable inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase with anticancer activity.
Eflapegrastim V69277 Eflapegrastim 1384099-30-2 Eflapegrastim is a humanized IgG4 monoclonal antibody (mAb) and a granulocyte colony-stimulating factor (G-CSF).
Emactuzumab (RG 7155; RO 5509554) V69273 Emactuzumab (RG 7155; RO 5509554) 1448221-67-7 Emactuzumab (RG 7155) is a specific monoclonal antibody (mAb) that can inhibit activation of the colony-stimulating factor 1 receptor (CSF1R).
IACS-9439 V69289 IACS-9439 2231259-36-0 IACS-9439 is a specific, orally bioactive CSF1R inhibitor (antagonist) with a Ki of 1 nM.
KI-20227 V23228 KI-20227 623142-96-1 KI-20227 is a potent and orally bioavailable inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively).
Lacnotuzumab (MCS110; Anti-Human B7-H3) V69276 Lacnotuzumab (MCS110; Anti-Human B7-H3) 1831128-32-5 Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody (mAb) that targets CSF-1 and prevents CSF-1 from activating the CSF-1R.
Contact Us